The biggest European pharmaceutical company faced a potential $3.3 billion U.S. government fine, over allegations that the company paid kickbacks to pharmacies who agreed to prescribe their drugs. But this week the company announced a settlement in the case, resolving the outstanding massive claims for far less.

The claims against the company were resolved in a $390 million settlement, according to Bloomberg. The company is off the hook for potentially illegal deals with pharmacies relating to five of its drugs: Tasigna, Gleevec, TOBI, Exjade and Myfortic.

The government’s case against Novartis stated that since 2005, the company has been giving pharmacies illegal rebates in return for prescribing Exjade and Myfortic over cheaper, generic alternatives. In addition, some pharmacies submitted fraudulent reimbursement claims to the government Medicaid and Medicare health plans.

A Novartis spokesman stated that the company was neither denying nor admitting liability in the settlement.

Compared to other recent settlements the Novartis case was resolved cheaply for the company. In 2012 drug maker GlaxoSmithKline (GSK) paid $3 billion in a settlement with the government over alleged illegal marketing practices and failure to conduct required clinical tests on certain drugs.

Novartis received more bad news this week, when its eye-care unit Alcon reported lower than expected earnings. Alcon is partnering with Google to develop “smart” contact lenses that can offer users health monitoring, but the products are not yet on the market. For now, the company faces tough competition from other leading eye care firms including Bausch & Lomb Inc. and Abbott Laboratories.